DRD1 and Lewy body dementia: There has been tremendous recent progress in the development of novel D1R positive allosteric modulators (PAMs) [24,25,26,27,28,29] in concert with X-ray crystal [30] and cryo-EM structures [31,32] that have revealed fascinating structural insights into the therapeutic potential of the D1R. This has culminated in the clinical evaluation of the first D1R PAM LY3154207 (Mevidalen) [33] which is currently in phase 2 for the amelioration of cognition associated with Lewy body dementias.